Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Galena Biopharma, Inc. (SLS) had Return on Equity of -326.27% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-30.88M |
|
-- |
|
-- |
|
$31.51M |
|
$-31.51M |
|
$0.63M |
|
$-30.88M |
|
$-30.88M |
|
$-30.88M |
|
$-30.88M |
|
$-30.88M |
|
$-30.88M |
|
$-31.51M |
|
$-31.51M |
|
61.20M |
|
61.20M |
|
$-0.50 |
|
$-0.50 |
|
| Balance Sheet Financials | |
$16.33M |
|
-- |
|
$3.10M |
|
$19.43M |
|
$9.51M |
|
-- |
|
$0.46M |
|
$9.97M |
|
$9.46M |
|
$7.55M |
|
$9.46M |
|
73.98M |
|
| Cash Flow Statement Financials | |
$-35.40M |
|
$0.00M |
|
$46.76M |
|
$2.63M |
|
$13.99M |
|
$11.36M |
|
$1.56M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.40M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-326.27% |
-408.97% |
|
-158.92% |
|
-326.27% |
|
$0.13 |
|
$-0.58 |
|
$-0.58 |
|